Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines

BACKGROUND: Gefitinib is a tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) especially effective in tumors with activating EGFR gene mutations while EGFR wild-type non small cell lung cancer (NSCLC) patients at present do not benefit from this treatment. The primary sit...

Full description

Saved in:
Bibliographic Details
Main Authors: Alfieri, Roberta R, Galetti, Maricla, Tramonti, Stefano, Andreoli, Roberta, Mozzoni, Paola, Cavazzoni, Andrea, Bonelli, Mara, Fumarola, Claudia, La Monica, Silvia, Galvani, Elena, De Palma, Giuseppe, Mutti, Antonio, Mor, Marco, Tiseo, Marcello, Mari, Ettore, Ardizzoni, Andrea, Petronini, Pier Giorgio
Format: Artigo
Language:Inglês
Published: BioMed Central 2011
Subjects:
Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3281800/
https://ncbi.nlm.nih.gov/pubmed/22111840
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-4598-10-143
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items